palivizumab 100 MG per 1 ML Injection
- RxCUI
- 1657341
- RxNorm name
- palivizumab 100 MG per 1 ML Injection
- Display name
- palivizumab 100 MG per 1 ML Injection
- Full name
- palivizumab 100 MG per 1 ML Injection
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:54
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 103770 | Synagis | palivizumab | 351(a) | Disc | 2026-10-01 |
UNII Substances#
No records found.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 3a0096c7-8139-44cd-bba4-520ab05c2cb2 | palivizumab 100 MG in 1 ML Injection [PSN] · 1 ML palivizumab 100 MG/ML Injection [SCD] · palivizumab 100 MG per 1 ML Injection [SY] | 3 | 8 | These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS ® (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998 | 20260121 |